A five year court battle in Wales, UK over a misdiagnosis has come to an end with damages awarded in the amount of £350,000
23 year old Laviana Bletchly was a student at the University of Wales Institute in Cardiff when, shortly after giving birth to her second child in May 2004, she began having pelvic and abdominal pain. Several exams followed, which found nothing until an ultrasound in February 2005 showed a cyst. Otherwise, Bletchly's complaints were largely ignored by her doctors, who often told her that her symptoms were merely in her head.
She would be admitted to the hospital many times over the coming weeks, until a CT scan and exploratory surgery revealed she had tumors from her bowel to her stomach.
Diagnosed with non-Hodgkin's lymphoma (subtype not mentioned in news reports), she underwent chemotherapy but died less than three weeks after the CT scan.
The settlement money, coming from the Abertawe Bro Morgannwg NHS Trust, responsible for her care, is meant to care for Bletchly's two young children.
Sources: Wales Online and The Mirror
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...